8-K: NewAmsterdam Pharma to Restate Prior Financials Due to Share Calculation Errors

NewAmsterdam Pharma will restate its financial statements for 2021 and 2022 due to errors in calculating net loss per ordinary share.

Summary

• NewAmsterdam Pharma's Audit Committee has determined that the company's previously issued financial statements for the years ending December 31, 2021 and 2022, should no longer be relied upon.
• The error stems from incorrect calculations of the weighted average ordinary shares outstanding, which led to misstated net loss per ordinary share figures.
• The company erroneously used the number of ordinary shares outstanding at the end of each period instead of the weighted average number of shares.
• These errors were found in the financial statements prepared under International Financial Reporting Standards (IFRS) and included in the 2022 Annual Report.
• The company's financial statements for the year ended December 31, 2023, which were prepared under US GAAP, are not affected by these errors.
• NewAmsterdam Pharma plans to restate the affected financial statements in an amendment to the 2022 Annual Report and will file it with the SEC as soon as practicable.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the restatement of financial statements, which indicates a material weakness in the company's accounting practices. This will likely cause investor concern.

Positives

• The company has identified the error and is taking steps to correct it.
• The company's 2023 financials are not affected by the error.
• The company is working to rectify the issue as quickly as possible.

Negatives

• The company's previously issued financial statements for 2021 and 2022 can no longer be relied upon.
• There were errors in the calculation of net loss per ordinary share.
• The restatement will require additional work and filings with the SEC.

Risks

• The restatement of financial statements could lead to investor uncertainty and potential loss of confidence.
• There is a risk of increased scrutiny from regulators and investors.
• The process of restating financials may be time-consuming and costly.

Future Outlook

The company intends to restate the affected financial statements in an amendment to the 2022 Annual Report and file it with the SEC as soon as practicable.

Management Comments

• The Audit Committee, after consultation with management and the independent auditor, concluded that the previously issued financial statements should not be relied upon.
• Management discussed the matter with Deloitte Accountants B.V., the company's independent registered public accounting firm.

Industry Context

Restatements of financial statements are not uncommon, but they can raise concerns about a company's internal controls and accounting practices. This event may lead investors to scrutinize NewAmsterdam Pharma's financial reporting more closely.

Comparison to Industry Standards

• While restatements occur across industries, they are often viewed negatively by investors. Companies like Valeant Pharmaceuticals (now Bausch Health) and Toshiba have faced significant market repercussions after restating financials.
• The impact on NewAmsterdam Pharma will depend on the magnitude of the restatement and how quickly the company can restore investor confidence. Companies with strong internal controls and transparent communication tend to recover more quickly.
• Compared to other pharmaceutical companies, the impact of this restatement will be closely watched by investors, as the sector is sensitive to financial reporting issues.

Stakeholder Impact

• Shareholders may experience a negative impact on the stock price due to the restatement.
• Creditors may reassess their risk exposure to the company.
• Employees may experience uncertainty due to the financial restatement.

Next Steps

• The company will restate the affected financial statements in an amendment to the 2022 Annual Report.
• The company will file the amended report with the Securities and Exchange Commission as soon as practicable.

Key Dates

Keywords

financial restatement, net loss per share, weighted average shares, IFRS, SEC filing, accounting error, audit committee, financial statements